US Patent

US9855215 — Methotrexate composition

Formulation · Assigned to Rosemont Pharmaceuticals Ltd · Expires 2033-01-02 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method of manufacturing a Methotrexate composition for oral administration by mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent.

USPTO Abstract

A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Drugs covered by this patent

Patent Metadata

Patent number
US9855215
Jurisdiction
US
Classification
Formulation
Expires
2033-01-02
Drug substance claim
No
Drug product claim
Yes
Assignee
Rosemont Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.